<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Drug Approval on FinanClub</title>
    <link>https://finan.club/tags/drug-approval/</link>
    <description>Recent content in Drug Approval on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 15 Apr 2024 09:02:28 +0000</lastBuildDate><atom:link href="https://finan.club/tags/drug-approval/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>GERN</title>
      <link>https://finan.club/us/gern/</link>
      <pubDate>Mon, 15 Apr 2024 09:02:28 +0000</pubDate>
      
      <guid>https://finan.club/us/gern/</guid>
      <description>score:82
Chances: Geron Corporation&amp;rsquo;s pipeline candidate, imetelstat, received FDA Committee backing for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes, indicating potential for successful drug approval and market adoption. Risks: The company recently announced an underwritten offering of its common stock and pre-funded warrants, which may dilute existing shareholders&amp;rsquo; ownership and impact stock performance in the short term.</description>
    </item>
    
  </channel>
</rss>
